drugset
drugset / Trial / NCT02601625

A Study to Assess the Pharmacokinetics and Safety of Single Doses of Anifrolumab in Healthy Subjects

NCT02601625 ↗

Phase 1 Completed 30 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

This is a Phase I, Randomized, Placebo-Controlled, Double-Blind Study to Assess the Pharmacokinetics and Safety of anifrolumab following Single-Dose administration to healthy subjects

Timeline

Start
2015-11-16
Primary completion
2016-05-25
Completion
2016-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Anifrolumab Monoclonal antibody 300 mg Subcutaneous
Subject Anifrolumab Monoclonal antibody 600 mg Subcutaneous

Indications

No indication recorded.